Somatropin is a recombinant human growth hormone indicated for the treatment of growth hormone deficiency in children and adults, as well as Turner syndrome, Prader-Willi syndrome, Chronic Renal Insufficiency (chronic kidney disorder), and others. Somatropin stimulates linear growth (height), tissue growth, and lipid, protein, carbohydrate, and mineral metabolism. Injections of somatropin are used to treat growth hormone insufficiency in both adults and children. Growth hormone is a natural hormone produced by the body. Children with specific diseases such as Growth hormone deficiency (GHD),that hinder normal growth and development can potentially benefit from somatropin injections to accelerate their growth. In addition to being available as a powder in vials and cartridges to be combined with liquid and administered subcutaneously, somatropin injection is also available as a solution (liquid) in prefilled dosing pens and cartridges (under the skin). Adults often receive a somatropin injection once a day to replenish growth hormone. In individuals with human immunodeficiency virus (HIV) who have HIV-associated wasting syndrome, somatropin injection (Serostim) is used to enhance body weight and physical endurance. Injections of somatropin (Zorbtive) are used to treat growth hormone deficiency.
Global Somatropin Market is estimated to be valued at US$ 3.6 Bn in 2022 and is expected to exhibit a CAGR of 7.2% over the forecast period (2022-2030).
Figure 1: Global Somatropin Market Share (%) Analysis, By Dosage Form, 2022
Global Somatropin Market – Drivers
Product approval from regulatory authorities such as ANVISA (National Sanitary Surveillance Agency), for drugs of Somatropin is expected to drive growth of the global somatropin market over the forecast period.
Product approval from regulatory authorities such as ANVISA (National Sanitary Surveillance Agency), for drugs of Somatropin is expected to drive growth of the global somatropin market over the forecast period. For instance, in May 2019, ANVISA (National Sanitary Surveillance Agency), approved the biosimilars named Criscy (Somatropin), which is safe and effective in the treatment of patients with pathologies associated with growth hormone deficiency. Criscy (Somatropin) is manufactured by Cristalia, a pharmaceutical & biotechnological research and development company, which is headquartered in Sao Paulo, Brazil.
Increasing long term effect of growth hormone therapy on children with growth hormone deficiency is expected to drive the global somatropin market growth over the forecast period.
Increasing long term effect of growth hormone therapy on children with growth hormone deficiency is expected to drive the global somatropin market growth over the forecast period. For instance, according to the data published in the Journal Acta Biomedica, in 2020, a study was conducted among 252 short children with growth hormone deficiency, 63 with idiopathic short stature, 26 with small for gestational age, and 9 with Turner syndrome who were treated in King Abdullah International Medical Research Center, Jeddah, Saudi Arabia with growth hormone in 2018.
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 3.6 Bn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 7.2 % | 2030 Value Projection: | US$ 6.3 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Global Somatropin Market- Impact of the Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.
The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.
The COVID-19 pandemic has affected clinical trials drastically. For instance, on April 23, 2020, according to a survey conducted by Medidata Solutions, Inc., a company which markets and develops software as a service for clinical trials, conducted a survey which showed observations such as 63% of survey respondents reported that they had stopped recruiting new patients for ongoing clinical trials and 43% of the respondents had postponed their studies.
Moreover, since the COVID-19 virus outbreak in December 2019, the supply chain of growth hormone deficiency drugs was hampered and the somatropin market was affected in a negative way, however the market recovery was seen over the late phase of COVID-19.
Global Somatropin Market– Restraints
Increasing presence of alternative drugs for growth hormone deficiency is expected to hamper growth of the Global Somatropin Market over the forecast period.
For instance, according to the data published in the biostation which provides information about scientific data where in 2022, Sermorelin therapy is less expensive than human growth hormone treatment, sometimes by as much as 10%. Injection or a multi-dose auto pen are two alternatives for administration of drug.
Global Somatropin Market– Regional Analysis
On the basis of region, the Global Somatropin Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, Europe market is expected to witness significant growth, owing to key companies in market focusing on research and development activities for drug development for treatment indicated for Pediatric Growth Hormone Deficiency. For instance, on June 12, 2022, Novo Nordisk A/S, a global healthcare company headqutered in Denmark announced results of once-weekly Sogroya (somapacitan) injection in helping children achieve growth targets of annualized height velocity (AHV).1 The phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented at the Endocrine Society’s Annual Meeting (ENDO 2022) in Atlanta, Georgia (U.S.).
Figure 2: Global Somatropin Market Value (US$ Bn), by Region, 2022
Global Somatropin Market– Key Players
Major players operating in the Global Somatropin Market include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited.
Somatropin injection is used to replace growth hormone (a natural hormone produced by body) in adults and children with growth hormone deficiency. Somatropin injection is also used to increase growth in children with certain conditions that affect normal growth and development. Somatropin injection comes as a solution (liquid) in prefilled dosing pens and cartridges and also as a powder in vials and cartridges to be mixed with liquid to be injected subcutaneously (under the skin). When somatropin injection is given to replace growth hormone in adults, it is usually given once a day. Somatropin injection (Serostim) is used to increase body weight and physical endurance in patients with human immunodeficiency virus (HIV) who have HIV-associated wasting syndrome. Somatropin injection (Zorbtive) is used to treat short bowel syndrome in adults who are receiving additional nutrition or fluids from intravenous (IV) therapy. Somatropin is a human growth hormone (hGH) analog. It works by replacing growth hormones that are normally produced in the body, which may result in increased growth, body weight, and improved absorption of nutrients and fluids from the intestines.
Market Dynamics
Increasing product approval by regulatory authorities is expected to fuel growth of the global somatropin market over the forecast period. For instance, on January 13, 2022, Ascendis Pharma A/S, a company that manufactures pharmaceutical products announced that the European Commission (EC) granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the treatment of children and adolescents aged 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone (also known as growth hormone deficiency, or GHD). TransCon hGH is a prodrug of somatropin that provides sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients